CervoMed (CRVO) Competitors

Fate Therapeutics (NASDAQ:FATE) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Do insiders and institutionals have more ownership in FATE or CRVO?

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by insiders. Comparatively, 36.3% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts rate FATE or CRVO?

Fate Therapeutics currently has a consensus target price of $6.89, suggesting a potential upside of 241.03%. CervoMed has a consensus target price of $53.60, suggesting a potential upside of 397.68%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
CervoMed	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to FATE or CRVO?

In the previous week, Fate Therapeutics had 6 more articles in the media than CervoMed. MarketBeat recorded 19 mentions for Fate Therapeutics and 13 mentions for CervoMed. Fate Therapeutics' average media sentiment score of 0.18 beat CervoMed's score of -0.12 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is FATE or CRVO more profitable?

CervoMed has a net margin of -118.68% compared to Fate Therapeutics' net margin of -1,325.43%. CervoMed's return on equity of -44.11% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,325.43%	-45.88%	-33.95%
CervoMed	-118.68%	-44.11%	-39.81%

Which has stronger earnings & valuation, FATE or CRVO?

CervoMed has lower revenue, but higher earnings than Fate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$63.53M	3.62	-$160.93M	-$1.65	-1.22
CervoMed	$7.14M	9.31	-$2.17M	N/A	N/A

Which has more risk and volatility, FATE or CRVO?

Fate Therapeutics has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500. Comparatively, CervoMed has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Does the MarketBeat Community prefer FATE or CRVO?

Fate Therapeutics received 472 more outperform votes than CervoMed when rated by MarketBeat users. However, 100.00% of users gave CervoMed an outperform vote while only 68.28% of users gave Fate Therapeutics an outperform vote.

Company	Underperform	Outperform
Fate Therapeutics	Outperform Votes 480 68.28%	Underperform Votes 223 31.72%
CervoMed	Outperform Votes 8 100.00%	Underperform Votes No Votes

Summary

CervoMed beats Fate Therapeutics on 9 of the 16 factors compared between the two stocks.